What are alternative treatments to Entresto (sacubitril/valsartan) for a patient with chronic kidney disease?

Alternative Treatments to Entresto for CKD

For patients with CKD who cannot take Entresto, the primary alternatives are ACE inhibitors or ARBs combined with SGLT2 inhibitors, with the specific choice guided by albuminuria status, diabetes presence, and eGFR level.

Primary Alternative: RAS Inhibitors (ACE Inhibitors or ARBs)

The 2024 KDIGO guidelines provide clear direction for CKD patients requiring alternatives to Entresto:

For patients with albuminuria:

• Severely increased albuminuria (A3, G1-G4): Start an ACE inhibitor or ARB regardless of diabetes status (strong recommendation, 1B) 1
• Moderately increased albuminuria (A2, G1-G4): Start an ACE inhibitor or ARB, particularly if diabetic (1B for diabetes, 2C without diabetes) 1

Key implementation points:

• Use the highest approved tolerated dose to achieve proven benefits from clinical trials 1
• Continue therapy even when eGFR falls below 30 mL/min/1.73 m² 1
• Monitor creatinine and potassium within 2-4 weeks of initiation or dose changes 1
• Accept creatinine increases up to 30% within 4 weeks; only discontinue if exceeding this threshold 1

Essential Add-On: SGLT2 Inhibitors

SGLT2 inhibitors represent a critical component of modern CKD management and should be added to RAS inhibition:

• For type 2 diabetes with eGFR ≥20 mL/min/1.73 m²: SGLT2 inhibitor is strongly recommended (1A) 1
• For non-diabetic CKD with eGFR ≥20 mL/min/1.73 m²: SGLT2 inhibitor is recommended (evidence from guidelines) 1
• Once initiated, continue even if eGFR drops below 20 mL/min/1.73 m² unless not tolerated 1

This combination (RAS inhibitor + SGLT2 inhibitor) provides complementary renoprotective mechanisms and represents the current standard of care for CKD progression prevention.

Why Not Entresto in CKD?

Understanding when Entresto is inappropriate helps clarify alternatives:

Contraindications and cautions from FDA labeling:

• History of angioedema with ACE inhibitors or ARBs 2
• Concurrent use with ACE inhibitors (36-hour washout required) 2
• Severe renal impairment concerns regarding monitoring 2
• Higher risk of hypotension, hyperkalemia, and renal function decline requiring close monitoring 2

Clinical context: While research suggests sacubitril/valsartan may preserve renal function in some CKD populations 3, 4, the evidence base for ACE inhibitors/ARBs in CKD is more robust and longstanding, making them the preferred first-line agents when Entresto is not suitable.

Practical Management Algorithm

Step 1: Assess albuminuria and diabetes status

• A3 (severely increased) → ACE inhibitor or ARB mandatory
• A2 (moderately increased) → ACE inhibitor or ARB strongly suggested
• A1 (normal/mildly increased) → Consider ACE inhibitor or ARB for hypertension or heart failure indications 1

Step 2: Add SGLT2 inhibitor if:

• Type 2 diabetes present with eGFR ≥20 mL/min/1.73 m²
• Non-diabetic CKD with eGFR ≥20 mL/min/1.73 m² (emerging evidence supports use)

Step 3: Optimize dosing

• Titrate RAS inhibitor to maximum tolerated dose
• Target BP <120 mmHg systolic when tolerated 1

Step 4: Monitor and manage complications

• Check creatinine and potassium 2-4 weeks after changes 1
• Manage hyperkalemia with potassium-lowering strategies rather than stopping RAS inhibitor 1
• Accept creatinine increases up to 30% 1

Critical Pitfalls to Avoid

Do NOT combine multiple RAS inhibitors: Avoid any combination of ACE inhibitor, ARB, and direct renin inhibitor—this increases adverse events without additional benefit (1B recommendation) 1

Do NOT stop RAS inhibitors prematurely for:

• Hyperkalemia (manage potassium first with dietary restriction, diuretics, or potassium binders) 1
• Mild creatinine elevations <30% 1
• eGFR decline to <30 mL/min/1.73 m² (continue therapy) 1

Do consider dose reduction or discontinuation only for:

• Symptomatic hypotension unresponsive to volume management 1
• Uncontrolled hyperkalemia despite medical treatment 1
• Creatinine rise >30% within 4 weeks 1
• eGFR <15 mL/min/1.73 m² with uremic symptoms 1

Additional Considerations

For patients with heart failure and CKD specifically, the choice becomes more nuanced. The 2022 AHA/ACC/HFSA guidelines note that sacubitril/valsartan showed benefits in HFpEF patients with LVEF closer to 50% 5. If Entresto is contraindicated in this population, an ARB (particularly candesartan or valsartan) combined with SGLT2 inhibitor and mineralocorticoid receptor antagonist (if tolerated) represents the best alternative strategy.

Blood pressure targets: Aim for systolic BP <120 mmHg when tolerated, but individualize for patients with frailty, fall risk, or limited life expectancy 1.